The Immune Response Corporation's Auditors Expressed a Going-Concern

    Business Editors/Health/Medical Writers
    BIOWIRE2K

    CARLSBAD, Calif.--(BUSINESS WIRE)--April 1, 2005--The Immune Response Corporation (Nasdaq:IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis, announced today that in its 2004 financial statements included in the Company's Form 10-K filed last week, the audit opinion of Levitz, Zacks & Ciceric contained a going-concern qualification.
    Nasdaq's rules require Nasdaq-listed companies to publicly announce whenever a Form 10-K includes an audit opinion containing a going-concern qualification.

    About The Immune Response Corporation

    The Immune Response Corporation (Nasdaq:IMNR) is a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS). The Company's HIV products are based on its patented whole-killed virus technology, co-invented by Company founder Dr. Jonas Salk, to stimulate HIV immune responses. REMUNE(R), currently in Phase II clinical trials, is being developed as a first-line treatment for people with early-stage HIV. We have initiated development of a new immune-based therapy, IR103, which incorporates a second-generation immunostimulatory oligonucleotide adjuvant and is currently in Phase I/II clinical trials in Canada and the United Kingdom.
    The Immune Response Corporation is also developing an immune-based therapy for MS, NeuroVax(TM), which is currently in Phase II clinical trials and has shown potential therapeutic value for this difficult-to-treat disease.
    Please visit The Immune Response Corporation at www.imnr.com

    This news release contains forward-looking statements. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of REMUNE(R), NeuroVax(TM) or IR103; the uncertainty of successful completion of any such clinical trials; the fact that the Company has not succeeded in commercializing any drug; the risk that REMUNE(R), NeuroVax(TM) or IR103 might not prove to be effective as either a therapeutic or preventive vaccine; whether future trials will be conducted; and whether the results of such trials will coincide with the results of REMUNE(R), NeuroVax(TM) or IR103 in preclinical trials and/or earlier clinical trials. These risks, among others, are set forth in The Immune Response Corporation's SEC filings, including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2004, and its subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update the results of these forward-looking statements to reflect events or circumstances after today or to reflect the occurrence of unanticipated events.
    REMUNE(R) is a registered trademark of The Immune Response Corporation. NeuroVax(TM) is a trademark of The Immune Response Corporation.

--30--TM/la*

CONTACT: Investor Contact: The Immune Response Corporation Michael K. Green, 760-431-7080 info@imnr.com or Media Contact: Sam Brown Inc. Corporate Communication Laura Silver, 310-551-9940 silver@sambrown.com

KEYWORD: CALIFORNIA INDUSTRY KEYWORD: PHARMACEUTICAL BIOTECHNOLOGY MEDICAL PRODUCT SOURCE: The Immune Response Corporation

Copyright Business Wire 2005